Mind Cure Health (CSE: MCUR) has completed the beta testing phase for its proprietary bioinformatics platform. Referred to as PsyCollage, the tool has been developed to drive decision making for drug lead optimization while also assisting in the discovery of target receptors.
The completion of the beta test marks the achievement of the firms first quarter testing milestone for the technology. The platform is being developed by the company as a means of product discovery, with the development being led by Chief Scientific Officer Dr Ryan Hartwell.
The technology works by using predicative correlative statistical analytics of documented research within the field of psychedelics. The analytics is capable of dealing with biological data with large and complex data sets, with the platform evolving into a resource for discovery and analysis of target receptors, methods, and historical clinical data trial.
Sponsored · Silver47 Exploration Inc.
Following initial beta testing, the technology has lead to Mind Cure identifying a number of priority indications, including cluster headaches, neuropathic pain, traumatic brain injury and migraines.
“The PsyCollage platform was developed to help MINDCURE accelerate research and planning to identify the therapeutic potential of psychedelic compounds and inform our priority research programs. With this strategic focus, we’re reinforcing our commitment to accelerating research to solve how the world addresses pain and suffering, and substantiating our role as leaders in psychedelic science.”
Kelsey Ramsden, President & CEO
Additional use cases and commercialization scenarios for PsyCollage are currently being evaluated by the company as well, with the platform already having been deployed for product discovery and lead optimization.
Mind Cure Health last traded at $0.63 on the CSE.
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
